Amicus Therapeutics, Inc. (FRA:AM6)

Market Cap	3.82B +36.2%
Revenue (ttm)	540.16M +20.0%
Net Income	-23.09M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	22.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2
Open	12.10
Previous Close	12.10
Day's Range	12.10 - 12.10
52-Week Range	4.80 - 12.30
Beta	n/a
RSI	66.98
Earnings Date	Feb 18, 2026

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 499
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AM6

Financial Performance

In 2025, Amicus Therapeutics's revenue was $634.21 million, an increase of 20.05% compared to the previous year's $528.30 million. Losses were -$27.11 million, -51.68% less than in 2024.

Financial numbers in USD